News about Regeneron

Regeneron has lagged broader equities over the past two years mainly because Eylea sales are falling under biosimilar and other competition, although the newer high-dose version is performing well. In the second quarter, revenue rose 17% to $4.3 billion, global Dupixent sales reached $6 billion, up 38%, and collaboration revenue from Sanofi grew 51% to $2.2 billion. Non-GAAP earnings per share rose 11% to $14.29, but combined U.S. Eylea revenue fell 12% to about $1 billion. The author believes Regeneron can navigate the possible biosimilar threat to Dupixent in the early 2030s through a new formulation, replacement medicines in development and its own pipeline, including the weight-loss candidate olatorepatide, and expects competitive returns over the medium term.